Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lite Strategy, Inc.MEIP · Entity 7396 | Chief Medical Officer | July 02, 2020 | July 07, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lite Strategy, Inc.
Report date July 02, 2020 · Filed July 07, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.49 · Expires 2030-07-02 | Direct | 230,000 |
Reported balance
After 2020-07-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-02 · Grant · Acquired 230,000 · Balance 230,000 F1: One-quarter of such options shall vest on July 2, 2021 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 2, 2021. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.57 · Expires 2025-07-28 | Direct | 112,500 |
Reported balance
Holding disclosure · report date 2020-07-02 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 112,500 F2: All of such options are presently exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2026-07-29 | Direct | 135,000 |
Reported balance
Holding disclosure · report date 2020-07-02 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 135,000 F3: One-quarter of such options vested on July 29, 2017 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 29, 2017. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.83 · Expires 2027-07-06 | Direct | 135,000 |
Reported balance
Holding disclosure · report date 2020-07-02 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 135,000 F4: One-quarter of such options vested on July 6, 2018 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 6, 2018. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.33 · Expires 2028-06-22 | Direct | 100,000 |
Reported balance
Holding disclosure · report date 2020-07-02 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 100,000 F5: One-quarter of such options vested on June 22, 2019 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on June 22, 2019. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.28 · Expires 2028-07-12 | Direct | 130,000 |
Reported balance
Holding disclosure · report date 2020-07-02 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 130,000 F6: One-quarter of such options vested on July 12, 2019 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 12, 2019. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.52 · Expires 2029-07-01 | Direct | 230,000 |
Reported balance
Holding disclosure · report date 2020-07-02 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 230,000 F7: One-quarter of such options vested on July 1, 2020 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 1, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: One-quarter of such options shall vest on July 2, 2021 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 2, 2021.
F2: All of such options are presently exercisable.
F3: One-quarter of such options vested on July 29, 2017 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 29, 2017.
F4: One-quarter of such options vested on July 6, 2018 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 6, 2018.
F5: One-quarter of such options vested on June 22, 2019 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on June 22, 2019.
F6: One-quarter of such options vested on July 12, 2019 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 12, 2019.
F7: One-quarter of such options vested on July 1, 2020 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 1, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 02, 2020 Filed Jul 7, 2020 17:12 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 230,000 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0000899243-20-018613 · doc4.xml · derivative · entry 1 Mass Robert D. · CIK 0001522224 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2030-07-02 F1 · derivative.exercise_date: One-quarter of such options shall vest on July 2, 2021 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 2, 2021. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 19:36 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 230,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001209191-19-040987 · doc4.xml · derivative · entry 1 Mass Robert D. · CIK 0001522224 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2029-07-01 F1 · derivative.exercise_date: One-quarter of such Options shall vest on July 1, 2020 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 1, 2020. Read SEC document |
| August 06, 2018 Filed Aug 8, 2018 22:00 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | Tax withholdingCommon Stock | 17,709 | $3.75 | $66,408.75 |
DisclosureSEC source: 0001209191-18-045897 · doc4.xml · nonDerivative · entry 1 Mass Robert D. · CIK 0001522224 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,661 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 6, 2018, to satisfy tax withholding obligations that arose in connection with the delivery of shares underlying restricted stock units that vested on August 5, 2018. Read SEC document |
| July 12, 2018 Filed Jul 16, 2018 21:34 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $4.28 | $0.00 |
DisclosureSEC source: 0001209191-18-042686 · doc4.xml · derivative · entry 1 Mass Robert D. · CIK 0001522224 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2028-07-12 F1 · derivative.exercise_date: One-quarter of such Options shall vest on July 12, 2019 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 12, 2019. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 18:27 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $4.33 | $0.00 |
DisclosureSEC source: 0000899243-18-018106 · doc4.xml · derivative · entry 1 Mass Robert D. · CIK 0001522224 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-06-22 F1 · derivative.exercise_date: One-quarter of such Options shall vest on June 22, 2019 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on June 22, 2019. Read SEC document |
| July 06, 2017 Filed Jul 10, 2017 18:27 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantOption to purchase shares of common stock · Derivative | 135,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0001209191-17-044521 · doc4.xml · derivative · entry 1 Mass Robert D. · CIK 0001522224 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 555,556 Underlying: Common Stock par value $0.00000002 · 135,000 shares Expires 2027-07-06 F1 · derivative.exercise_date: One-quarter of the options will vest on July 6, 2018; the remaining three-quarters of the options will vest in equal monthly installments over the following thirty-six months. F2 · balance_after: The total number of derivative securities reported in Column 9 includes previously awarded options, which were subject to the effect of a 1 for 6 reverse stock split, which was effective on December 18, 2012. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.